A Phase II Prospective Non-Randomized Two-Arm Clinical Trial of Dose-Adjusted Schedule of Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma (CTCL) Who Did Not Receive Prior Systemic Therapy or Have Been Treated With Single Agent Targretin.

Trial Profile

A Phase II Prospective Non-Randomized Two-Arm Clinical Trial of Dose-Adjusted Schedule of Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma (CTCL) Who Did Not Receive Prior Systemic Therapy or Have Been Treated With Single Agent Targretin.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2014

At a glance

  • Drugs Vorinostat (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Oct 2012 Planned number of patients changed from 60 to 40.
    • 19 Jul 2012 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
    • 30 May 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top